Literature DB >> 18721831

Chromogranin peptides in amyotrophic lateral sclerosis.

A Schrott-Fischer1, M Bitsche, C Humpel, C Walcher, H Maier, K Jellinger, W Rabl, R Glueckert, J Marksteiner.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder which primarily affects motor neurons. Eight cases of ALS and seven control cases were studied with semiquantitative immunocytochemistry for chromogranin A, chromogranin B and secretogranin II that are soluble constituents of large dense core vesicles, synaptophysin as a membrane protein of small synaptic vesicles and superoxide dismutase 1. Among the chromogranin peptides, the number and staining intensity of motor neurons was highest for chromogranin A. In ALS, the staining intensity for chromogranin peptides and synaptophysin was significantly lower in the ventral horn of ALS patients due to a loss in immunoreactive motor neurons, varicose fibers and varicosities. For all chromogranins, the remaining motor neurons displayed a characteristic staining pattern consisting of an intracellular accumulation of immunoreactivity with a high staining intensity. Confocal microscopy of motor neurons revealed that superoxide dismutase 1-immunopositive intracellular aggregates also contained chromogranin A, chromogranin B and secretogranin II. These findings indicate that there is a loss of small and large dense core vesicles in presynaptic terminals. The intracellular co-occurrence of superoxide dismutase 1 and chromogranins may suggest a functional interaction between these proteins. This study should prompt further experiments to elucidate the role of chromogranins in ALS patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18721831     DOI: 10.1016/j.regpep.2008.07.009

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  14 in total

Review 1.  Chromogranins A and B as regulators of vesicle cargo and exocytosis.

Authors:  José D Machado; Jésica Díaz-Vera; Natalia Domínguez; Carmen M Alvarez; Marta R Pardo; Ricardo Borges
Journal:  Cell Mol Neurobiol       Date:  2010-11-03       Impact factor: 5.046

Review 2.  The extended granin family: structure, function, and biomedical implications.

Authors:  Alessandro Bartolomucci; Roberta Possenti; Sushil K Mahata; Reiner Fischer-Colbrie; Y Peng Loh; Stephen R J Salton
Journal:  Endocr Rev       Date:  2011-08-23       Impact factor: 19.871

Review 3.  Genetics of Amyotrophic Lateral Sclerosis.

Authors:  Mehdi Ghasemi; Robert H Brown
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

Review 4.  Chromogranin peptides in brain diseases.

Authors:  Michael Willis; Irmgard Leitner; Kurt A Jellinger; Josef Marksteiner
Journal:  J Neural Transm (Vienna)       Date:  2011-04-30       Impact factor: 3.575

5.  Chromogranin B P413L variant as risk factor and modifier of disease onset for amyotrophic lateral sclerosis.

Authors:  Francois Gros-Louis; Peter M Andersen; Nicolas Dupre; Makoto Urushitani; Patrick Dion; Frederique Souchon; Monique D'Amour; William Camu; Vincent Meininger; Jean-Pierre Bouchard; Guy A Rouleau; Jean-Pierre Julien
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-09       Impact factor: 11.205

6.  Cerebrospinal fluid levels of chromogranin A in the treatment-naïve early stage Parkinson's disease: a pilot study.

Authors:  Michaela Kaiserová; Hana Přikrylová Vranová; David Stejskal; Kateřina Menšíková; Petr Kaňovský
Journal:  J Neural Transm (Vienna)       Date:  2013-04-16       Impact factor: 3.575

Review 7.  Secretory granules in inositol 1,4,5-trisphosphate-dependent Ca2+ signaling in the cytoplasm of neuroendocrine cells.

Authors:  Seung Hyun Yoo
Journal:  FASEB J       Date:  2009-10-16       Impact factor: 5.191

Review 8.  Recent advances in our understanding of neurodegeneration.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2009-06-05       Impact factor: 3.575

9.  Monitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinic.

Authors:  Nils von Neuhoff; Tonio Oumeraci; Thomas Wolf; Katja Kollewe; Peter Bewerunge; Boris Neumann; Benedikt Brors; Johannes Bufler; Ulrich Wurster; Brigitte Schlegelberger; Reinhard Dengler; Marc Zapatka; Susanne Petri
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

10.  Proteomic Characterization of Cerebrospinal Fluid from Ataxia-Telangiectasia (A-T) Patients Using a LC/MS-Based Label-Free Protein Quantification Technology.

Authors:  Monika Dzieciatkowska; Guihong Qi; Jinsam You; Kerry G Bemis; Heather Sahm; Howard M Lederman; Thomas O Crawford; Lawrence M Gelbert; Cynthia Rothblum-Oviatt; Mu Wang
Journal:  Int J Proteomics       Date:  2011-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.